SCHEMBL24654166

SCHEMBL24654166

CC(C)CCCNC(=O)C1(C)CCOC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.36
LMNA P02545 3/20 0.36
HPGD P15428 2/20 0.36
NPSR1 Q6W5P4 2/20 0.35
ALDH1A1 P00352 2/20 0.34
CETP P11597 1/20 0.34
POLB P06746 1/20 0.33
TSHR P16473 1/20 0.31
MEN1 O00255 1/20 0.30
MAPT P10636 1/20 0.30
HTT P42858 1/20 0.30
RECQL P46063 1/20 0.30
KMT2A Q03164 1/20 0.30
ITGAV P06756 1/20 0.30
ITGB6 P18564 1/20 0.30
SPHK1 Q9NYA1 3/20 0.30
DRD2 P14416 1/20 0.30
DRD4 P21917 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29306394 0.84 CYP3A4 (0.43) CYP3A4CYP2C19SMN1; SMN2LMNAHPGD
SCHEMBL24654071 0.81 SPHK1 (0.47) SMN1; SMN2LMNAHPGDNPSR1ALDH1A1
SCHEMBL24654080 0.81 CYP3A4 (0.41) CYP3A4CYP2C19SMN1; SMN2LMNAHPGD
SCHEMBL25632161 0.81 DRD2 (0.42) CYP3A4CYP2C19SMN1; SMN2LMNAHPGD
SCHEMBL24654083 0.80 DRD2 (0.44) CYP3A4CYP2C19SMN1; SMN2LMNAHPGD
SCHEMBL29306462 0.79 CYP3A4 (0.37) CYP3A4CYP2C19SMN1; SMN2LMNAHPGD
SCHEMBL25564851 0.78 ALDH1A1 (0.33) CYP3A4CYP2C19SMN1; SMN2LMNAHPGD
SCHEMBL24654072 0.75 GLS (0.42) CYP3A4CYP2C19SMN1; SMN2LMNAHPGD
SCHEMBL19199227 0.73 SMN1; SMN2 (0.42) CYP3A4CYP2C19SMN1; SMN2LMNAHPGD
SCHEMBL26717052 0.72 CYP3A4 (0.38) CYP3A4CYP2C19SMN1; SMN2LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226026-A1 BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ARES CAPITAL CORPORATION, AS AGENT 2024-07-11 US disclosed
WO-2022204288-A1 BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS MODERNATX, INC. (US) 2022-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226026-A1 BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS PLTP, LNPK, PLIN3 CYP3A4 4877/4885CYP2C19 4874/4885SMN1; SMN2 1663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.